Get the Stockscreener App
2.27
1.30%
-0.03
After Hours:
2.22
-0.05
-2.20%
Elutia Inc stock is traded at $2.27, with a volume of 14,100.
It is down -1.30% in the last 24 hours and down -22.26% over the past month.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
See More
Previous Close:
$2.30
Open:
$2.37
24h Volume:
14,100
Relative Volume:
0.34
Market Cap:
$87.45M
Revenue:
$24.38M
Net Income/Loss:
$-53.95M
P/E Ratio:
-0.919
EPS:
-2.47
Net Cash Flow:
$-23.31M
1W Performance:
+6.07%
1M Performance:
-22.26%
6M Performance:
-30.58%
1Y Performance:
-22.26%
1-Day Range:
$2.07
$2.37
1-Week Range:
$2.05
$2.37
52-Week Range:
$1.87
$5.24
Elutia Inc Stock (ELUT) Company Profile
Name
Elutia Inc
Sector
Industry
Phone
240-247-1143
Address
12510 PROSPERITY DRIVE, SILVER SPRING
Compare ELUT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELUT
Elutia Inc
|
2.27 | 87.45M | 24.38M | -53.95M | -23.31M | -2.47 |
|
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Elutia Inc Stock (ELUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-02-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-02-20 | Initiated | Cowen | Outperform |
| Nov-02-20 | Initiated | Piper Sandler | Overweight |
| Nov-02-20 | Initiated | Truist | Buy |
Elutia Inc Stock (ELUT) Latest News
Elutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29 | ELUT Stock News - GuruFocus
Elutia's Top Scientist Reveals Drug Development Strategy: Key Regulatory Catalysts in Focus - Stock Titan
Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29 - TradingView
Elutia (ELUT) Begins EluPro Clinical Study to Enhance Patient Outcomes | ELUT Stock News - GuruFocus
Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice | ELUT Stock News - GuruFocus
Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice - The Manila Times
Elutia Inc. Initiates Clinical Study for EluPro™ to Enhance Cardiac Device Outcomes - Nasdaq
Elutia Begins Landmark Registry Study for Revolutionary CIED Protection Technology EluPro - Stock Titan
Elutia (ELUT) Reports Resilience Amid Global Tariff Changes | EL - GuruFocus
Elutia Confirms No Material Impact from Global Tariffs | ELUT St - GuruFocus
Elutia unaffected by global tariffs, maintains US focus By Investing.com - Investing.com South Africa
Elutia unaffected by global tariffs, maintains US focus - Investing.com Canada
Elutia Unaffected by Global Tariffs Due to US-Based Operations - marketscreener.com
Elutia Confirms No Material Impact from Global Tariffs - The Manila Times
US-Made Medical Devices: How Elutia Dodges Global Tariff Pressures - Stock Titan
Elutia Inc May Offer & Sell Up To $50.0 Million Of Shares Of Class A Common StockSEC Filing - MarketScreener
Elutia Brokers GPO Agreement with Advantus Health Partners - Medical Product Outsourcing
Eluta Slumps on Recognition - Baystreet.ca
EluPro™ Named as 2025 Edison Award Winner - The Manila Times
Revolutionary Medical Device EluPro Clinches Edison Award: Game-Changer for 600,000 Annual Heart Implants - Stock Titan
Elutia to Participate in Upcoming Investor Conferences - TradingView
Exclusive Investor Access: Elutia CEO to Showcase Drug-Eluting Innovation at Premier Conferences - Stock Titan
AIGH Capital Management LLC Has $11.50 Million Position in Elutia Inc. (NASDAQ:ELUT) - MarketBeat
Elutia to Debut EluPro™ at HRS 2025Experience the Difference Biology Makes - The Manila Times
Elutia to Debut EluPro™ at HRS 2025 — Experience the Difference Biology Makes - TradingView
Revolutionary Biological CIED Protection: Elutia Unveils Dual-Antibiotic EluPro Technology - Stock Titan
Elutia Inc. reports mixed preliminary 2024 financial results - MSN
Elutia Inc. secures deal with Advantus Health Partners By Investing.com - Investing.com South Africa
Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro?? - MarketScreener
Elutia Enters GPO Deal With Advantus Health Partners - MarketScreener
Elutia Inc. secures deal with Advantus Health Partners - Investing.com
Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™ - The Manila Times
Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro - TradingView
Healthcare Milestone: Elutia Secures 7th GPO Deal for Revolutionary Antibiotic Device - Stock Titan
Elutia publishes new preclinical data in Antibiotics - TipRanks
Elutia Advances Scientific Leadership with Publication of New Study on Antibiotic-Eluting Biologic Envelope - The Manila Times
Groundbreaking Clinical Data: Elutia's FDA-Cleared Device Eliminates All Tested Bacteria - Stock Titan
Elutia Files For Mixed Shelf Of Up To $100 MillionSEC Filing -March 18, 2025 at 06:23 am EDT - Marketscreener.com
Elutia stock soars, Anteris falls in medical devices sector By Investing.com - Investing.com South Africa
Elutia stock soars, Anteris falls in medical devices sector - Investing.com India
HighCape Capital buys $1.05 million in Elutia Inc. stock - Investing.com India
HighCape Capital buys $1.05 million in Elutia Inc. stock By Investing.com - Investing.com South Africa
Elutia Inc. sees $1.05 million stock purchase by HighCape entities - Investing.com Australia
Elutia Inc. Reports Strong Demand for EluPro™ - TipRanks
ELUTIA INC. SEC 10-K Report - TradingView
Elutia Inc. (ELUT) reports earnings - qz.com
Earnings call transcript: Elutia Q4 2024 misses forecasts, stock drops By Investing.com - Investing.com Australia
Elutia’s (ELUT) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World
Earnings call transcript: Elutia Q4 2024 misses forecasts, stock drops - Investing.com India
Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-Out - The Manila Times
Elutia Inc (ELUT) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Product Growth ... - Yahoo Finance
Elutia Inc Stock (ELUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):